Seagen, A Wholly Owned Subsidiary Of Pfizer

This study is for people with advanced bladder cancer that has spread and cannot be removed by surgery, and whose tumors have a protein called HER2. Researchers are testing a drug called disitamab vedotin, either alone or with another drug called pembrolizumab, to see if it can s…

This early-stage study tests an experimental drug called PF-08046050 in adults with advanced solid tumors (like lung, colon, or stomach cancer) that have come back or not improved with standard treatments. The drug is designed to stick to cancer cells and kill them. The main goal…

This early-stage study tests a new drug called sigvotatug vedotin, alone or with other cancer drugs, in people with advanced solid tumors like lung, head and neck, and breast cancer. The goal is to find a safe dose and check for side effects. About 1,000 participants will take pa…

This study tests whether adding tucatinib and trastuzumab to standard chemotherapy helps people with HER2-positive colorectal cancer that has spread or can't be removed. About 400 participants will be randomly assigned to the new combo or standard treatment. The goal is to see if…

This early-stage study tests a new drug, PF-08046054/SGN-PDL1V, in people with advanced solid tumors that have spread or can't be removed. The goal is to find a safe dose and check for side effects, both when the drug is given alone and with another cancer drug called pembrolizum…

This early-stage trial tests a new drug called SEA-CD70, alone or with standard treatments, in people with two types of blood cancer: myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The main goals are to find safe doses and check for side effects. About 178 adult…

This study tests a new combination of drugs for people with advanced breast or stomach cancers that have a protein called HER2. The experimental drug disitamab vedotin is designed to stick to cancer cells and kill them, and it is combined with the approved drug tucatinib. The goa…